TW202444706A - N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 - Google Patents

N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 Download PDF

Info

Publication number
TW202444706A
TW202444706A TW113128176A TW113128176A TW202444706A TW 202444706 A TW202444706 A TW 202444706A TW 113128176 A TW113128176 A TW 113128176A TW 113128176 A TW113128176 A TW 113128176A TW 202444706 A TW202444706 A TW 202444706A
Authority
TW
Taiwan
Prior art keywords
hydrochloride
crystalline form
chlorodifluoromethoxy
hydroxypyrrolidin
pyrazol
Prior art date
Application number
TW113128176A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂芬妮 凱 達德
阿諾德 葛連德瑞
維吉尼亞 羅薩基
艾曼紐 瑟福爾特
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW202444706A publication Critical patent/TW202444706A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW113128176A 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀 TW202444706A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962848857P 2019-05-16 2019-05-16
US62/848,857 2019-05-16
US201962949599P 2019-12-18 2019-12-18
US62/949,599 2019-12-18

Publications (1)

Publication Number Publication Date
TW202444706A true TW202444706A (zh) 2024-11-16

Family

ID=70775449

Family Applications (2)

Application Number Title Priority Date Filing Date
TW113128176A TW202444706A (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
TW109116067A TWI853027B (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW109116067A TWI853027B (zh) 2019-05-16 2020-05-14 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Country Status (13)

Country Link
US (3) US11407735B2 (https=)
EP (1) EP3969117B1 (https=)
JP (2) JP2022532404A (https=)
KR (1) KR102945602B1 (https=)
CN (1) CN114144232A (https=)
AU (1) AU2020276701B2 (https=)
BR (1) BR112021022712A2 (https=)
CA (1) CA3139812A1 (https=)
CL (1) CL2021003011A1 (https=)
IL (1) IL287995A (https=)
MX (1) MX2021013970A (https=)
TW (2) TW202444706A (https=)
WO (1) WO2020230099A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202444706A (zh) 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
WO2021154980A1 (en) 2020-01-28 2021-08-05 Teva Pharmaceuticals International Gmbh Solid state forms of asciminib and processes for the preparation thereof
WO2022206937A1 (zh) * 2021-04-01 2022-10-06 苏州晶云药物科技股份有限公司 一种吡唑取代的烟酰胺类化合物的盐酸盐新晶型及其制备方法
CN114369085B (zh) * 2021-12-27 2023-01-03 武汉九州钰民医药科技有限公司 盐酸Asciminib的制备方法
WO2024100212A1 (en) 2022-11-10 2024-05-16 Synthon B.V. Crystalline form of asciminib hydrochloride
WO2024257116A1 (en) * 2023-06-13 2024-12-19 Natco Pharma Limited Novel polymorphic forms of asciminib and its pharmaceutical salts thereof
WO2025032514A1 (en) * 2023-08-07 2025-02-13 Biophore India Pharmaceuticals Pvt. Ltd A process for the preparation of solid forms of n-[4(chlorodifluoromethoxy)phenyl]-6-[(3r)-3-hydroxypyrrolidin-1-yl]-5-(1h-pyrazol-3-yl) pyridine-3-carboxamide hydrogen chloride

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4920215A1 (es) 1997-02-14 2000-05-29 Novartis Ag Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
EP1248869A2 (en) * 2000-01-07 2002-10-16 Transform Pharmaceuticals, Inc. High-throughput formation, identification, and analysis of diverse solid-forms
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2013171642A1 (en) 2012-05-15 2013-11-21 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PE20161416A1 (es) * 2012-05-15 2017-01-08 Novartis Ag Derivados de benzamida para la inhibicion de la actividad abl1, abl2 y bcr-abl1
RU2647421C2 (ru) 2012-12-27 2018-03-15 Зентива Саглык Урунлеры Сан. Ве Тыдж. А.Ш. Способ сухого гранулирования для получения композиций метформина в виде таблеток и его композиции
CA2954840A1 (en) 2014-07-25 2016-01-28 Novartis Ag Tablet formulation of 2-fluoro-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
EP3120851A1 (en) 2015-07-21 2017-01-25 Pangaea Biotech S.L. 4-amino-6-(2,6-dichlorophenyl)-8-methyl-2-(phenylamino)-pyrido[2,3-d]pyrimidin-7(8h)-one for treatment of solid cancers
US9931342B2 (en) 2016-02-02 2018-04-03 Duke University Compositions and methods for the treatment of cancer
EP3292870A1 (en) 2016-09-08 2018-03-14 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Fibronectin for use in the treatment of leukemia
WO2018060843A1 (en) 2016-09-27 2018-04-05 Novartis Ag Surfactant systems for crystallization of organic compounds
US11065243B2 (en) 2017-10-27 2021-07-20 Sonic Master Limited Inhibitors of DUX4 induction for regulation of muscle function
WO2019232244A2 (en) 2018-05-31 2019-12-05 Novartis Ag Antibody molecules to cd73 and uses thereof
TW202444706A (zh) * 2019-05-16 2024-11-16 瑞士商諾華公司 N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀

Also Published As

Publication number Publication date
AU2020276701B2 (en) 2023-11-23
WO2020230099A1 (en) 2020-11-19
TWI853027B (zh) 2024-08-21
CA3139812A1 (en) 2020-11-19
AU2020276701A8 (en) 2022-05-12
JP2024095697A (ja) 2024-07-10
JP2022532404A (ja) 2022-07-14
US11407735B2 (en) 2022-08-09
TW202110823A (zh) 2021-03-16
US20200361904A1 (en) 2020-11-19
US12252479B2 (en) 2025-03-18
US20230089503A1 (en) 2023-03-23
CL2021003011A1 (es) 2022-09-09
EP3969117B1 (en) 2026-03-25
US20230074064A1 (en) 2023-03-09
CN114144232A (zh) 2022-03-04
KR20220009414A (ko) 2022-01-24
KR102945602B1 (ko) 2026-03-31
EP3969117A1 (en) 2022-03-23
MX2021013970A (es) 2022-01-04
AU2020276701A1 (en) 2022-01-06
BR112021022712A2 (pt) 2022-03-29
US12252478B2 (en) 2025-03-18
IL287995A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
TWI853027B (zh) N-[4-(氯二氟甲氧基)苯基]-6-[(3r)-3-羥基吡咯啶-1-基]-5-(1h-吡唑-5-基)吡啶-3-甲醯胺之結晶形狀
TWI849124B (zh) 新的結晶形狀
TWI619495B (zh) Ｃ-ｍｅｔ調節劑醫藥組合物
JP3760264B2 (ja) アリピプラゾール水和物、アリピプラゾール無水物結晶、それらの製造方法及びそれらを含む製剤
CN110621662A (zh) 一种盐的结晶性固体形式、制备工艺和使用方法
HRP20041048A9 (hr) POLIMORF 4-[2-[4-[1-(2-ETOKSIETIL)-1H-BENZIMIDAZOL-2-IL]-1-PIPERIDINIL]ETIL]-α, α- DIMETIL- BENZENOCTENE KISELINE
TWI815820B (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
HRP20000328A2 (en) Novel polymorph v of torasemide
RU2836337C2 (ru) Кристаллические формы n-[4-(хлордифторметокси)фенил]-6-[(3r)-3-гидроксипирролидин-1-ил]-5-(1h-пиразол-5-ил)пиридин-3-карбоксамида
US20240293420A1 (en) Pharmaceutical composition, preparation, and preparation method therefor and use thereof
KR20260055492A (ko) N-[4-(클로로디플루오로메톡시)페닐]-6-[(3r)-3-히드록시피롤리딘-1-일]-5-(1h-피라졸-5-일)피리딘-3-카복사미드의결정질 형태
HK40127061A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390B (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
HK40065390A (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer